April 2020 Newsletter

Golden Helix Software Discounted for COVID-19 Related Projects

We have announced our latest efforts to help assist the clinical research community in this battle by offering significantly discounted 18-month software licenses for anyone researching or working on projects related to COVID-19.

For more than 20 years, Golden Helix has focused on our mission to empower precision medicine around the world. We want you to know you have our commitment to continue providing you with the products and services you depend on during these unprecedented times. Read More

Genetic Analysis of the COVID-19 Virus and Other Pathogens: Part I

New eBook: Genetic Analysis of the COVID-19 Virus and Other Pathogens

In this eBook, I summarize to the best of my knowledge our current understanding of COVID-19 and the virus SARS-Cov-2 causing it. Most of the papers that I used to prepare this eBook were published since the beginning of this year. The body of knowledge is quickly expanding and evolving. Next-Generation Sequencing (NGS) can deliver significant insights in this process. This eBook outlines how NGS can be used and how Golden Helix software solutions can be utilized in the process. ... Read More

Featured in The Journal of Precision Medicine: Best Practices for NGS-Based Cancer Diagnostics

It is an honor to be published in The Journal of Precision Medicine’s March 2020 issue where I have outlined the current best practices for NGS-based cancer diagnostics. In this article, I detail The need to standardize clinical reporting Popular annotation sources and functional prediction algorithms The AMP Guidelines and how these can be applied with Golden Helix’s Diagnostic Platform for Cancer... Read More

Detecting de Novo Copy Number Inheritance and Family Segregations

In trio workflows, one of the most important factors in scoring a variant is understanding how that variant is inherited from the parents. Likewise, when looking at extended families, the segregation, or presence of the variant among the affected versus unaffected individuals provides evidence for its pathogenicity for a given phenotype or disease. Given the nature of Copy Number Variants (CNVs) as large events being detected from variable depth Next-Gen Sequencing (NGS) data, it is difficult to consistently call the exact same start and stop positions between samples... Read More

CEO Corner

Last month I released my latest eBook "Genetic Analysis of the COVID-19 Virus and Other Pathogens" which outlines how research and clinicians alike can use our software to research SARS-CoV-2 as well as in a clinical space. We are currently working with a number of labs that are active in this space and anticipate publishing a few interesting findings. In the meantime, we are offering anyone involved with COVID-19 work special considerations which can be found here. I hope you stay safe as we continue to push forward through these uncertain times, we are in this together.

Upcoming Webcast

Next-Gen Sequencing of the SARS-CoV-2 Virus with Golden Helix
May 6, 2020 | 12:00 PM Eastern

The COVID-19 outbreak is an unprecedented event in terms of its impact on public health and the global economy. While we may see the development of an immunization strategy as the ultimate solution, sequencing the virus with Next-Generation Sequencing (NGS) provides useful diagnostic and research findings to impact the course of this pandemic. As a provider of NGS analysis solutions spanning clinical and research capabilities, Golden Helix has a number of analytical solutions relevant to these different use cases for the analysis of the SARS-CoV-2 virus.

Customer Success

Congratulations to all of our customers who have published this month! To highlight just a few:

"Mixed Ancestry from Wild and Domestic Lineages Contributes to the Rapid Expansion of Invasive Feral Swine"
- Timothy Smyser & Colleagues, National Wildlife Research Center / Published in Molecular Ecology

"Quantitative Proteomic Landscape of Metaplastic Breast Carcinoma Pathological Subtypes and Their Relationship to Triple-negative Tumors"
- University of Michigan / Published in Nature Communications

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.